Benzo[c][1,8]naphthyridin-6 (5H) -one

Benzo[c][1,8]naphthyridin-6 (5H) -one exhibits low micromolar affinity to human adenosine receptor (AR) A1 and hA2A, with Ki of 4.6 and 4.8 μM. Benzo[c][1,8]naphthyridin-6 (5H) -one is inhibitor for poly ADP-ribose polymerase-1 (PARP-1) and aurora kinase A, with IC50 of 0.311 and 5.5 μM[1][2][3].

Product Specifications

CAS Number

[53439-81-9]

UNSPSC

12352005

Hazard Statement

H315-H319-H320

Target

Adenosine Receptor; Aurora Kinase; PARP

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Epigenetics; GPCR/G Protein

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/benzo-c-1-8-naphthyridin-6-5h-one.html

Smiles

O=C1NC2=NC=CC=C2C3=CC=CC=C13

Molecular Formula

C12H8N2O

Molecular Weight

196.20

Precautions

P264-P280-P302+P352-P305+P351+P338-P362

References & Citations

[1]van der Horst E, et al., Multi-objective evolutionary design of adenosine receptor ligands. J Chem Inf Model. 2012 Jul 23;52 (7) :1713-21.|[2]Ferraris D, et al., Design and synthesis of poly ADP-ribose polymerase-1 inhibitors. 2. Biological evaluation of aza-5[H]-phenanthridin-6-ones as potent, aqueous-soluble compounds for the treatment of ischemic injuries. J Med Chem. 2003 Jul 3;46 (14) :3138-51. |[3]Karra S, et al., SAR and evaluation of novel 5H-benzo[c][1,8]naphthyridin-6-one analogs as Aurora kinase inhibitors. Bioorg Med Chem Lett. 2013 May 15;23 (10) :3081-7.